SRZNW — Surrozen Inc. Warrant
NASDAQ · Healthcare · Biotechnology
$0.00
+$0.00 (+153.33%)
Surrozen Inc. Warrant (SRZNW) is a biotechnology company listed on NASDAQ. It is led by Craig C. Parker M.B.A., based in 171 Oyster Point Boulevard, South San Francisco, CA, United States, 94080, with about 40 employees. Surrozen, Inc., a biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair. Its lead product candidates are antibody-based therapeutics that target various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system. The company develops SZN-814, which combines Frizzled 4 (Fzd4 agonism) and vascular endothelial growth factor (VEGF antagonism) to treat diabetic macular edema (DME), neovascular age-related macular degeneration (wet AMD), and retinopathy indications; SZN-8143, which combines Fzd4 agonism, VEGF antagonism, and interleukin-6 for the treatment of DME/wet AMD/uveitic macular edema; SZN-113 to treat Fuchs' endothelial corneal dystrophy and geographic atrophy; and SZN-413, a Fzd4 targeted bi-specific antibody for the treatment of retinal vascular associated diseases. Surrozen, Inc. has a collaboration and license agreement with Boehringer Ingelheim International GmbH to research, develop, and commercialize Fzd4 bi-specific antibodies; and a research collaboration agreement with TCGFB, Inc. to discover antibody therapeutics targeting transforming growth factor beta, or TGF-ß, for the treatment of pulmonary fibrosis. Surrozen, Inc. is headquartered in South San Francisco, California.
Latest reported SRZNW revenue for 2025-09-30 was $983.0K. Net income was -$71.6M.
Use this SRZNW page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the SRZNW quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the SRZNW SEC filings page. Lician reads the product cache first so this HTML stays unique to Surrozen Inc. Warrant even when a live quote feed is slow.
About Surrozen Inc. Warrant
Surrozen, Inc., a biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair. Its lead product candidates are antibody-based therapeutics that target various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system. The company develops SZN-814, which combines Frizzled 4 (Fzd4 agonism) and vascular endothelial growth factor (VEGF antagonism) to treat diabetic macular edema (DME), neovascular age-related macular degeneration (wet AMD), and retinopathy indications; SZN-8143, which combines Fzd4 agonism, VEGF antagonism, and interleukin-6 for the treatment of DME/wet AMD/uveitic macular edema; SZN-113 to treat Fuchs' endothelial corneal dystrophy and geographic atrophy; and SZN-413, a Fzd4 targeted bi-specific antibody for the treatment of retinal vascular associated diseases. Surrozen, Inc. has a collaboration and license agreement with Boehringer Ingelheim International GmbH to research, develop, and commercialize Fzd4 bi-specific antibodies; and a research collaboration agreement with TCGFB, Inc. to discover antibody therapeutics targeting transforming growth factor beta, or TGF-ß, for the treatment of pulmonary fibrosis. Surrozen, Inc. is headquartered in South San Francisco, California.
SRZNW Key Statistics
Market Cap
$0.00M
Volume
26,468
Previous Close
$0.00
Day Range
$0.00 – $0.00
EPS
-$21.67
Revenue
$10.65M
Net Income
-$63.56M
Gross Profit
$0.00
Free Cash Flow
$0.00
Profit Margin
-596.6%
Employees
40
SRZNW Financials
Annual income statement in USD. Latest reported periods first.
| Line | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|
| Revenue | $10.65M | $0.00 | $0.00 | $0.00 |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross Profit | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating Income | $0.00 | $0.00 | $0.00 | $0.00 |
| Net Income | -$63.56M | -$43.04M | -$36.00M | -$54.65M |
| EPS (Diluted) | -$21.67 | -$21.33 | -$15.56 | -$2.21 |
Total Assets
$48.47M
Total Debt
$0.00
Shareholders' Equity
$0.00
Cash & Equivalents
$34.56M
Operating Cash Flow
-$17.63M
Free Cash Flow
$0.00
Surrozen Inc. Warrant Company Information
- CEO, President & Director
- Craig C. Parker M.B.A.
- Headquarters
- 171 Oyster Point Boulevard, South San Francisco, CA, United States, 94080
- Website
- www.surrozen.com
- Phone
- 650 489 9000
- IPO / Founded
- 2021-08-12
- Sector
- Healthcare
- Industry
- Biotechnology